This is a short overview of how to use Anderson criteria as modification to RECIST 1.1 to measure bone lesions. The criteria was developed by The University of Texas MD Anderson Cancer Center back in 2004 and is gaining popularity in clinical research because it allows patient who would be considered as not having measurable disease per RECIST 1.1 to be included in clinical trials.
You can learn more about this criteria here: Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST


Please follow and like us: